Fig. 3

Foxp3-MSC monotherapy achieves donor-specific liver allograft tolerance. a Kaplan–Meier survival curves for untreated, donor-derived MSC, FUGW-MSC and Foxp3-MSC, recipient-derived Foxp3-MSC and third party Foxp3-MSC groups. b Kaplan–Meier survival curves for the Foxp3-MSC, Foxp3-MSC+IgG and Foxp3-MSC+α-CD25 groups. c Histology of liver allografts in ACI recipients on POD 7 (H&E, original magnification ×100). d RAI scores according to the Banff scheme. Results are mean ± SE of five independent experiments. *p < 0.05 vs untreated; ^# p < 0.05 vs MSC. e, f Changes in the serum ALT, AST and TBIL concentrations in all 4 groups 7 days after LT. Results are mean ± SE of three independent experiments. *p < 0.05 vs untreated; ^# p < 0.05 vs MSC. g Representative skin biopsy samples were obtained on day 7 and 100 after skin transplantation (H&E, original magnification ×100)